BeyondSpring to Present New Therapy at AACR Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BYSI?
Source: Newsfilter
- Conference Presentation: BeyondSpring will showcase its poster titled 'Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates' at the 2026 Annual Meeting of the American Association for Cancer Research, highlighting the company's ongoing innovation in cancer treatment.
- Presentation Details: The poster will be presented on April 21, 2026, from 2 PM to 5 PM at the San Diego Convention Center, which is expected to attract significant attention from industry experts, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Research Context: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting unmet medical needs in non-small cell lung cancer, showcasing BeyondSpring's potential in cancer therapy.
- Strategic Implications: By presenting at the AACR meeting, BeyondSpring not only demonstrates its research achievements but also strengthens connections with investors and industry experts, paving the way for future collaborations and investment opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BYSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BYSI
About BYSI
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BeyondSpring to Present New Therapy at AACR Annual Meeting
- Conference Presentation: BeyondSpring will showcase its poster titled 'Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates' at the 2026 Annual Meeting of the American Association for Cancer Research, highlighting the company's ongoing innovation in cancer treatment.
- Presentation Details: The poster will be presented on April 21, 2026, from 2 PM to 5 PM at the San Diego Convention Center, which is expected to attract significant attention from industry experts, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Research Context: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting unmet medical needs in non-small cell lung cancer, showcasing BeyondSpring's potential in cancer therapy.
- Strategic Implications: By presenting at the AACR meeting, BeyondSpring not only demonstrates its research achievements but also strengthens connections with investors and industry experts, paving the way for future collaborations and investment opportunities.
See More
BeyondSpring Files Annual Report for 2025
- Annual Report Submission: BeyondSpring filed its annual report on Form 10-K with the SEC on March 25, 2026, detailing its audited consolidated financial statements for the fiscal year ending December 31, 2025, reflecting the company's progress in clinical-stage biopharmaceutical development.
- Financial Transparency: The annual report is accessible on both the SEC's website and the company's website, ensuring that investors can easily review the company's financial health, thereby enhancing trust between the company and its shareholders.
- Core Asset Development: BeyondSpring's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer, with its unique mechanism aiding in restoring tumor sensitivity to checkpoint inhibitors, showcasing the company's potential to address high unmet medical needs.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements that highlight risks and uncertainties related to future operations, such as challenges in raising necessary funds and potential delays in regulatory approvals, urging investors to consider market competition and the unpredictability of clinical trial outcomes.
See More
BeyondSpring Reports FY 2025 Financial Results
- Financial Overview: BeyondSpring reported a FY 2025 GAAP EPS of -$0.21, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $12.6 million in cash, cash equivalents, and short-term investments, suggesting a buffer in liquidity management but raising concerns about future funding needs.
- Investor Concerns: With ongoing losses and limited cash reserves, BeyondSpring may need to seek additional financing to support its R&D and operations, increasing the risk to future financial stability.
- Market Reaction Expectations: Investors may react cautiously to the earnings report, particularly given the company's lack of profitability, which could lead to stock price volatility and decreased market confidence.
See More
BeyondSpring to Present at IO360° Conference 2026
- Conference Participation: BeyondSpring will participate in the Immuno-Oncology 360° Conference from February 10-12, 2026, in Boston, showcasing its latest advancements in cancer immunotherapy to enhance its visibility and influence in the biopharmaceutical industry.
- Leadership Presentation: Dr. Lan Huang, Co-Founder and CEO, will present on Plinabulin on February 11 from 4:55 PM to 5:10 PM, highlighting its unique mechanism and clinical development strategy, which is expected to attract attention from investors and industry experts.
- Innovative Mechanism: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting high unmet medical needs in indications like non-small cell lung cancer, demonstrating its potential in cancer treatment.
- Post-Presentation Materials: Following the presentation, the slides will be available on the company's website under the
See More
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
- Surge in Acquisition Proposals: ZIM Integrated Shipping has received multiple competitive acquisition proposals during its strategic review, with the board evaluating these offers to create significant value for shareholders, which is expected to enhance the company's market appeal.
- Stock Price Rebound: Following the announcement, ZIM's shares rose 7.6% in pre-market trading to $21.38, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Enhanced Strategic Value: By actively assessing acquisition proposals, ZIM not only strengthens its market position but also may achieve operational efficiencies through resource integration, thereby delivering higher returns to shareholders.
- Positive Market Reaction: The stock price increase indicates investor confidence in ZIM's potential acquisitions, which could further boost the company's competitiveness and market share in the shipping industry.
See More
BeyondSpring Reports Significant Survival Improvement for Plinabulin in Asian NSCLC Patients
- Survival Rate Improvement: In a cohort of nearly 500 Asian patients, the Plinabulin plus docetaxel treatment group (DP) achieved an overall survival of 10.8 months compared to 8.8 months for docetaxel alone, with a hazard ratio of 0.81 and a p-value of 0.0426, indicating the drug's potential in EGFR wild-type non-small cell lung cancer (NSCLC) patients.
- Safety Advantage: Plinabulin significantly reduced the incidence of grade 4 neutropenia caused by docetaxel (DP: 3.9% vs. D: 26.5%, p<0.0001), which not only enhances patient tolerability but also may increase the efficacy of chemotherapy, thereby improving the overall treatment experience for patients.
- Mechanism Relevance: In the mechanism-aligned non-squamous subgroup, Plinabulin demonstrated a 3-month survival benefit (p=0.0064), indicating stronger efficacy of its immune-modulating and tumor vasculature-targeting mechanisms in specific patient populations, further solidifying its potential as a new standard of care.
- Global Study Advancement: BeyondSpring's CEO stated that these data bolster confidence in Plinabulin as a new standard treatment for EGFR wild-type NSCLC and will propel it into a global Phase 3 confirmatory study, showcasing the company's strategic positioning in the oncology field.
See More
BeyondSpring to Present New Therapy at AACR Annual Meeting
- Conference Presentation: BeyondSpring will showcase its poster titled 'Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates' at the 2026 Annual Meeting of the American Association for Cancer Research, highlighting the company's ongoing innovation in cancer treatment.
- Presentation Details: The poster will be presented on April 21, 2026, from 2 PM to 5 PM at the San Diego Convention Center, which is expected to attract significant attention from industry experts, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Research Context: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting unmet medical needs in non-small cell lung cancer, showcasing BeyondSpring's potential in cancer therapy.
- Strategic Implications: By presenting at the AACR meeting, BeyondSpring not only demonstrates its research achievements but also strengthens connections with investors and industry experts, paving the way for future collaborations and investment opportunities.
See More
BeyondSpring Files Annual Report for 2025
- Annual Report Submission: BeyondSpring filed its annual report on Form 10-K with the SEC on March 25, 2026, detailing its audited consolidated financial statements for the fiscal year ending December 31, 2025, reflecting the company's progress in clinical-stage biopharmaceutical development.
- Financial Transparency: The annual report is accessible on both the SEC's website and the company's website, ensuring that investors can easily review the company's financial health, thereby enhancing trust between the company and its shareholders.
- Core Asset Development: BeyondSpring's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer, with its unique mechanism aiding in restoring tumor sensitivity to checkpoint inhibitors, showcasing the company's potential to address high unmet medical needs.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements that highlight risks and uncertainties related to future operations, such as challenges in raising necessary funds and potential delays in regulatory approvals, urging investors to consider market competition and the unpredictability of clinical trial outcomes.
See More
BeyondSpring Reports FY 2025 Financial Results
- Financial Overview: BeyondSpring reported a FY 2025 GAAP EPS of -$0.21, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $12.6 million in cash, cash equivalents, and short-term investments, suggesting a buffer in liquidity management but raising concerns about future funding needs.
- Investor Concerns: With ongoing losses and limited cash reserves, BeyondSpring may need to seek additional financing to support its R&D and operations, increasing the risk to future financial stability.
- Market Reaction Expectations: Investors may react cautiously to the earnings report, particularly given the company's lack of profitability, which could lead to stock price volatility and decreased market confidence.
See More
BeyondSpring to Present at IO360° Conference 2026
- Conference Participation: BeyondSpring will participate in the Immuno-Oncology 360° Conference from February 10-12, 2026, in Boston, showcasing its latest advancements in cancer immunotherapy to enhance its visibility and influence in the biopharmaceutical industry.
- Leadership Presentation: Dr. Lan Huang, Co-Founder and CEO, will present on Plinabulin on February 11 from 4:55 PM to 5:10 PM, highlighting its unique mechanism and clinical development strategy, which is expected to attract attention from investors and industry experts.
- Innovative Mechanism: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting high unmet medical needs in indications like non-small cell lung cancer, demonstrating its potential in cancer treatment.
- Post-Presentation Materials: Following the presentation, the slides will be available on the company's website under the
See More
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
- Surge in Acquisition Proposals: ZIM Integrated Shipping has received multiple competitive acquisition proposals during its strategic review, with the board evaluating these offers to create significant value for shareholders, which is expected to enhance the company's market appeal.
- Stock Price Rebound: Following the announcement, ZIM's shares rose 7.6% in pre-market trading to $21.38, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Enhanced Strategic Value: By actively assessing acquisition proposals, ZIM not only strengthens its market position but also may achieve operational efficiencies through resource integration, thereby delivering higher returns to shareholders.
- Positive Market Reaction: The stock price increase indicates investor confidence in ZIM's potential acquisitions, which could further boost the company's competitiveness and market share in the shipping industry.
See More
BeyondSpring Reports Significant Survival Improvement for Plinabulin in Asian NSCLC Patients
- Survival Rate Improvement: In a cohort of nearly 500 Asian patients, the Plinabulin plus docetaxel treatment group (DP) achieved an overall survival of 10.8 months compared to 8.8 months for docetaxel alone, with a hazard ratio of 0.81 and a p-value of 0.0426, indicating the drug's potential in EGFR wild-type non-small cell lung cancer (NSCLC) patients.
- Safety Advantage: Plinabulin significantly reduced the incidence of grade 4 neutropenia caused by docetaxel (DP: 3.9% vs. D: 26.5%, p<0.0001), which not only enhances patient tolerability but also may increase the efficacy of chemotherapy, thereby improving the overall treatment experience for patients.
- Mechanism Relevance: In the mechanism-aligned non-squamous subgroup, Plinabulin demonstrated a 3-month survival benefit (p=0.0064), indicating stronger efficacy of its immune-modulating and tumor vasculature-targeting mechanisms in specific patient populations, further solidifying its potential as a new standard of care.
- Global Study Advancement: BeyondSpring's CEO stated that these data bolster confidence in Plinabulin as a new standard treatment for EGFR wild-type NSCLC and will propel it into a global Phase 3 confirmatory study, showcasing the company's strategic positioning in the oncology field.
See More
